查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591947

高膽固醇症治療藥物市場：按作用機制、疾病類型和藥物類別 - 全球預測 2025-2030

Hypercholesterolemia Drug Market by Mechanism of Action, Type of Disease (Familial hypercholesterolemia, Non-Familial hypercholesterolemia ), Drug Class - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

高膽固醇症治療市場2023年估值為202.5億美元，預計到2024年將達214.3億美元，複合年成長率為6.32%，預計到2030年將達到311億美元。

高膽固醇症血症藥物市場包括一系列旨在降低血液中高膽固醇水平（稱為高膽固醇症）的藥物治療。高膽固醇症會增加心血管疾病的風險，並且通常受到生活方式和遺傳因素的影響。這些藥物的需求是由於不健康的飲食、久坐的生活方式和人口老化等因素導致高膽固醇症在全球流行。這些藥物（如他汀類藥物、PCSK9 抑制劑、膽固醇吸收抑制劑和 bempedoic 酸）的應用範圍和最終用途正在擴大，因為醫療保健提供者透過各種製劑直接向患者給藥。市場開拓洞察表明，關鍵的成長要素是心血管健康意識的不斷提高以及研究和開發的進步，這些進步促進了療效和安全性更高的新藥的開發。此外，不斷成長的醫療保健支出和旨在降低心血管疾病發病率的政府措施也推動了市場擴張。然而，藥品成本上漲、嚴格監管和潛在副作用等挑戰可能會阻礙成長。一個顯著的機會在於生技藥品和個人化醫療，它們有望提供具有潛在較少副作用的標靶治療選擇。公司可以透過投資創新的藥物輸送系統並利用人工智慧和資料分析來個人化患者照護來抓住這些機會。限制包括學名藥的競爭以及需要大規模臨床試驗來檢驗新治療方法。鑑於市場的動態特性，以技術快速進步和消費者偏好不斷變化為特徵，創新和研究正在推動以患者為中心的解決方案的開發，加強患者對數位健康工具的依從性，並重點應放在探索聯合治療上血脂管理。總體而言，高膽固醇症治療市場提供了巨大的成長機會，但也存在需要策略導航和持續創新的挑戰。

主要市場統計
基準年[2023] 202.5億美元
預測年份 [2024] 214.3億美元
預測年份 [2030] 311億美元
複合年成長率（%） 6.32%

市場動態：揭示快速發展的高高膽固醇症治療市場的關鍵市場洞察

高膽固醇症藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球心臟病發病率不斷上升
    • 不健康飲食習慣的增加以及便利性食品和加工食品消費的增加
    • 私人和公共實體增加消費者醫療保健和基礎設施支出
  • 市場限制因素
    • 市場上替代品的可用性
    • 消費者健康意識與健康飲食習慣
  • 市場機會
    • 新藥引進的科技進步
    • 跨地區聯合治療的使用增加
  • 市場挑戰
    • 品牌藥與學名藥之間的競爭

波特的五力戰略工具駕馭高膽固醇症藥物市場

波特的「五力」框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解高膽固醇症藥物市場的外部影響

外部宏觀環境因素在塑造高膽固醇症治療藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解高膽固醇症治療藥物市場的競爭狀況

高膽固醇症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣高高膽固醇症市場供應商的績效評估

FPNV 定位矩陣是評估高膽固醇症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃高膽固醇症治療藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對高膽固醇症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球心臟病發生率增加
      • 不健康飲食習慣的增加以及簡便食品和加工食品的消費增加
      • 私營和公共部門增加消費者醫療保健和基礎設施支出
    • 抑制因素
      • 市場上替代品的可用性
      • 消費者對健康和健康飲食的認知
    • 機會
      • 新藥引進的科技進步
      • 全部區域聯合治療的使用增加
    • 任務
      • 品牌藥與學名藥之間的競爭
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章高膽固醇症治療藥物市場按作用機制

  • 膽汁酸螯合劑
  • 纖維酸衍生物
  • HMG-CoA還原酶抑制劑
  • 菸鹼酸

第7章依疾病類型分類的高膽固醇症治療藥物市場

  • 遺傳性高膽固醇症（FH）
  • 遺傳性高膽固醇症（FH）

第8章按藥物類別分類的高膽固醇症治療藥物市場

  • 非他汀類藥物
  • 他汀類藥物

第9章北美和南美高高膽固醇症血症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區高膽固醇症血症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的高膽固醇症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • AtheroNova Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-43127F727989

The Hypercholesterolemia Drug Market was valued at USD 20.25 billion in 2023, expected to reach USD 21.43 billion in 2024, and is projected to grow at a CAGR of 6.32%, to USD 31.10 billion by 2030.

The hypercholesterolemia drug market encompasses a range of pharmaceutical treatments aimed at lowering high levels of cholesterol in the blood, a condition known as hypercholesterolemia. This condition increases the risk of cardiovascular diseases and is often influenced by lifestyle and genetic factors. The necessity of these drugs stems from the significant global prevalence of hypercholesterolemia, driven by factors such as unhealthy diets, sedentary lifestyles, and an aging population. The application and end-use scope of these drugs are widespread, involving direct administration to patients by healthcare providers through various formulations like statins, PCSK9 inhibitors, cholesterol absorption inhibitors, and bempedoic acid, among others. Market insights reveal that a major growth driver is the rising awareness of cardiovascular health, coupled with advances in R&D facilitating the development of novel drugs that offer improved efficacy and safety profiles. Additionally, increasing healthcare spending and government initiatives targeted at reducing cardiovascular disease incidences bolster market expansion. However, challenges such as high drug costs, stringent regulatory pathways, and potential side effects may hamper growth. A notable opportunity lies in biologics and personalized medicine, which promise targeted treatment options with potentially fewer side effects. Companies are advised to invest in innovative drug delivery systems and leverage AI and data analytics for personalized patient care to seize these opportunities. Limitations include generic competition and the necessity for large-scale clinical trials to validate new treatments. Given the dynamic nature of the market, characterized by rapid technological advancements and shifting consumer preferences, innovation and research should focus on developing patient-centric solutions, enhancing patient adherence through digital health tools, and exploring combination therapies for comprehensive lipid management. Overall, the hypercholesterolemia drug market presents significant opportunities for growth, albeit with challenges that demand strategic navigation and continuous innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 20.25 billion
Estimated Year [2024] USD 21.43 billion
Forecast Year [2030] USD 31.10 billion
CAGR (%) 6.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of heart disorders worldwide
    • Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
    • Increasing consumer healthcare spending and infrastructure spending by private and public organizations
  • Market Restraints
    • Availability of alternative substitutes in the market
    • Consumer awareness on healthy and fit diet
  • Market Opportunities
    • Technological advancements in introduction of novel drugs
    • Rising utilization of combination therapies across regions
  • Market Challenges
    • Competition from generic versions of branded drugs

Porter's Five Forces: A Strategic Tool for Navigating the Hypercholesterolemia Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hypercholesterolemia Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hypercholesterolemia Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hypercholesterolemia Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hypercholesterolemia Drug Market

A detailed market share analysis in the Hypercholesterolemia Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hypercholesterolemia Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hypercholesterolemia Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hypercholesterolemia Drug Market

A strategic analysis of the Hypercholesterolemia Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypercholesterolemia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., AstraZeneca PLC, AtheroNova Inc., Aurobindo Pharma Limited, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, Esperion Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals Inc., Mylan N.V., Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Hypercholesterolemia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism of Action, market is studied across Bile Acid Sequestrants, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors, and Nicotinic Acid.
  • Based on Type of Disease, market is studied across Familial hypercholesterolemia (FH) and Non-Familial hypercholesterolemia (FH).
  • Based on Drug Class, market is studied across Non-Statins and Statins.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of heart disorders worldwide
      • 5.1.1.2. Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
      • 5.1.1.3. Increasing consumer healthcare spending and infrastructure spending by private and public organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative substitutes in the market
      • 5.1.2.2. Consumer awareness on healthy and fit diet
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in introduction of novel drugs
      • 5.1.3.2. Rising utilization of combination therapies across regions
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from generic versions of branded drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hypercholesterolemia Drug Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Bile Acid Sequestrants
  • 6.3. Fibric Acid Derivatives
  • 6.4. HMG-CoA Reductase Inhibitors
  • 6.5. Nicotinic Acid

7. Hypercholesterolemia Drug Market, by Type of Disease

  • 7.1. Introduction
  • 7.2. Familial hypercholesterolemia (FH)
  • 7.3. Non-Familial hypercholesterolemia (FH)

8. Hypercholesterolemia Drug Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Non-Statins
  • 8.3. Statins

9. Americas Hypercholesterolemia Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hypercholesterolemia Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hypercholesterolemia Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Alnylam Pharmaceuticals Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. AtheroNova Inc.
  • 6. Aurobindo Pharma Limited
  • 7. Cipla Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dr. Reddy's Laboratories Ltd
  • 10. Eli Lilly and Company
  • 11. Esperion Therapeutics, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Ionis Pharmaceuticals Inc.
  • 14. Mylan N.V.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYPERCHOLESTEROLEMIA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYPERCHOLESTEROLEMIA DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FIBRIC ACID DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NICOTINIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023